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Recent studies have used conditional knockout mice to selectively delete
the D2 autoreceptor; however, these approaches result in global deletion of
D2 autoreceptors early in development. The present study takes a different approach
using RNA interference (RNAi) to knockdown the expression of the D2 receptors (D2R)
in the substantia nigra (SN), including dopaminergic neurons, which project primarily
to the dorsal striatum (dStr) in adult rats. This approach restricts the knockdown
primarily to nigrostriatal pathways, leaving mesolimbic D2 autoreceptors intact. Analyses
of dopamine (DA) kinetics in the dStr reveal a decrease in DA transporter (DAT) function
in the knockdown rats, an effect not observed in D2 autoreceptor knockout mouse
models. SN D2 knockdown rats exhibit a behavioral phenotype characterized by
persistent enhancement of locomotor activity in a familiar open field, reduced locomotor
responsiveness to high doses of cocaine and the ability to overcome haloperidol-
induced immobility on the bar test. Together these results demonstrate that presynaptic
D2R can be depleted from specific neuronal populations and implicates nigrostriatal
D2R in different behavioral responses to psychotropic drugs.
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INTRODUCTION
Alterations in dopamine (DA) neurotransmission are associated with many neuropsychiatric
conditions including schizophrenia, attention deficit hyperactivity disorder and drug addiction.
DA uptake via the presynaptic DA transporter (DAT) is essential for controlling synaptic DA
concentrations. D2 receptors (D2R) located on presynaptic dopaminergic neurons participate
in regulating synaptic DA concentrations by increasing DA uptake (Cass and Gerhardt, 1994;
Dickinson et al., 1999; Wu et al., 2002), while also inhibiting DA release (May and Wightman,
1989; Kawagoe et al., 1992; Wu et al., 2002) and synthesis (Budygin et al., 1999a,b) when activated
Abbreviations: BACT, beta-actin gene; DRD2, D2 dopamine receptor gene; [DA]p, DA release per pulse; dStr, dorsal
striatum; ENO2, Enolase 2 gene; FSCV, fast scan cyclic voltammetry; SCR, scrambled.
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by excessive DA levels. These D2 autoreceptors may participate
in DA-related pathologies and represent a potential therapeutic
target. However, D2 autoreceptors are difficult to study due
to their diverse neuroanatomical localization in multiple brain
regions and the presence of D2R on both pre- and post-synaptic
sites, as well as the lack of pharmacological reagents that can
target each population independently. Being able to separate
presynaptic D2 autoreceptor function from postsynaptic D2R
in specific brain regions such as the striatum is essential in
determining their roles in various neurological conditions.
Until recently, we have not been able to independently
manipulate the D2 autoreceptor without also affecting
postsynaptic receptors. The first successful effort to genetically
target presynaptic D2R was accomplished by Bello et al. (2011)
using a floxed-D2R mouse crossed with a strain expressing
Cre-recombinase in DAT neurons (Dat+/IRES–cre). In these
animals the D2R were deleted only in dopaminergic neurons
while leaving post-synaptic D2R intact. The phenotype of
these mice included hyperactivity, increased sensitivities to
DAT blockers such as cocaine and methylphenidate, as well
as increased sensitivity to typical and atypical antipsychotics
including haloperidol and sulpiride, respectively. More recently,
Anzalone et al. (2012) used a similar approach by crossing
floxed-D2R mice with a mutant strain in which the Engrailed-1
promoter drives Cre expression (En1Cre) in the brain. En1Cre
mice express Cre in multiple embryonic sites, including the
mid-hindbrain junction in the early embryo (Srinivas et al.,
2001), resulting in loss of D2 autoreceptors from projections of
the midbrain. The mice demonstrated a phenotype similar to
that reported by Bello et al. (2011) with some notable exceptions
in presynaptic DA dynamics and responses to dopaminergic
drugs. For example, the autoreceptor knockdown line reported
by Bello et al exhibited enhanced electrically evoked DA release
and no change in its reuptake, while Anzalone et al. (2012)
showed an attenuation of DA release and enhancement of
reuptake.
Given the role of D2R in fine-tuning DA neurotransmission,
it is possible the primary mechanism underlying these
discrepancies may be developmental compensation due to
chronic hyperdopaminergia, which could obscure the functional
role of the D2 autoreceptor. In addition, both mutant strains
have a global deletion of D2 autoreceptors in both striatonigral
and mesolimbic pathways. Thus having a model in which
D2 autoreceptors are deleted acutely in adult animals to avoid
developmental compensation, and in a brain region specific
manner, could better clarify the role of the autoreceptor in
various behaviors and in response to pharmacological agents.
We have pursued a flexible RNA interference approach
to study the role of presynaptic D2 autoreceptors in the
nigrostriatal pathway of adult, wild type Sprague-Dawley rats.
An adeno-associated virus (AAV) was used to deliver a short
hairpin RNA (shRNA) targeting the D2R to the substantia
nigra (SN). Our data show that depletion of D2R from SN
neurons, (hereafter referred to as SN D2 knockdowns) alters
DA release and reuptake kinetics in the dorsal striatum (dStr).
In addition, the rats display enhanced locomotor activity,
suppressed locomotor responses to high, but not low, doses of
cocaine and an attenuated cataleptic response to haloperidol.
These results demonstrate the utility of this site-specific viral
vector approach in enhancing our understanding of how SN D2R
participate in regulating DA neurotransmission and responses to
dopaminergic agents.
MATERIALS AND METHODS
Materials
All experiments and procedures were approved either by the
Wake Forest School of Medicine or University at Buffalo, SUNY
Institutional Animal Care and Use Committees, followed the
guidelines of the NIH Guide for the Care and Use of Laboratory
Animals, and comply with the ARRIVE guidelines. Adult male
Sprague-Dawley rats weighing between 250–300 g were obtained
from Harlan Laboratories (Frederick, MD, USA). Animals were
housed two to a cage with food and water available ad libitum.
The facilities are under a standard 12/12 h light dark schedule
with lights off at 03:00 h and on at 15:00 h. All procedures
were conducted between the hours of 10:00 h and 13:00 h.
Viral Constructs: the shRNA-AAV plasmids were cloned as
previously described (Sadri-Vakili et al., 2010; Lazarus et al.,
2011). The enhanced green fluorescent protein (EGFP)-U6-
pACP plasmid contains AAV2 inverted terminal repeats (ITR)
flanking a cytomegalovirus promoter (CMV), the EGFP gene,
an intron and polyadenylation signal derived from SV40, and
further downstream, a murine U6 pol III promoter (mU6,
Figure 1A). Briefly, synthetic oligos encoding the shRNA
and its respective complement (Integrated DNA Technologies,
Coralville, IA, USA) were annealed and ligated into unique
BbsI and NheI sites downstream of the U6 promoter. Three
shRNAs were designed to target different regions of the rat
D2 mRNA (NM_012513). It should be noted that the shRNA
targets are found in both D2 short and D2 long receptor isoform
mRNA. The control vector, shSCR-AAV, encodes EGFP plus
a scrambled (SCR) shRNA, which does not correspond to any
known rat mRNA sequence. Packaging of all AAV using standard
transfection protocols to generate helper virus-free pseudotyped
AAV2/10 virus (Xiao et al., 1998) has been described elsewhere
(Bass et al., 2010). The vector stocks were titered by real-time
quantitative PCR using the ABI Prism 7700 Sequence Detection
System from Perkin-Elmer Applied Biosystems (Foster City, CA,
USA) as previously described (Clark et al., 1999). The average
titer of the preparations was approximately 1 × 1012 vector
genomes/ml. For all experiments, the three D2 shRNA viruses
were mixed and co-injected. Previous studies have demonstrated
that the co-administration of shRNAs with mixed knockdown
efficiencies can produce more than additive effects and a greater
knockdown than an individual shRNA alone (Bahi et al., 2005).
We have previously demonstrated the effectiveness of these
viruses in knocking down post-synaptic D2R in rat dStr (Blume
et al., 2013).
Stereotaxic Injections
Rats were anesthetized with 80 mg/kg ketamine and 12 mg/kg
xylazine (i.p.), placed in an adult rat stereotaxic frame (Kopf
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FIGURE 1 | Knockdown efficiency of D2 receptors (D2R)-shRNA
adeno-associated virus (AAV) in the substantia nigra (SN). (A) Top
shows a representative image of EGFP spread in the midbrain visualized with
immunohistochemistry for GFP (scale bar equals 600 µm, −6.11 mm from
bregma). Bottom is a graphic depiction of the transgene contained in the AAV
(ITR, inverted terminal repeat; CMV, cytomegalovirus promoter;
EGFP, enhanced green fluorescent protein; intron/pA, combined intron and
poly adenylation sequence; U6, mouse U6 promoter; shRNA, short hairpin
RNA). (B) Relative EGFP mRNA levels as determined by real time qPCR of SN
injected with scrambled (SCR) control or D2 shRNA-AAV (n = 4–6).
(C) Relative D2R mRNA levels in the SN and (D) dorsal striatum (dSTR),
∗p < 0.05.
Instruments, Tujunga, CA, USA) and an incision was made
along the midline of the scalp exposing bregma. Burr holes were
drilled over the injection site and a 10 µl syringe (Hamilton
Company, NV, USA) was inserted vertically above the SN (AP
−5.6 mm, ML ±2.0 mm, DV −7.6 mm). Animals were injected
with 0.5 µl D2R shRNA-AAV over a 5 min period with an
infusion rate ∼0.1 µl/min. The needle was maintained in place
for an additional 5 min and then slowly withdrawn. The incision
was sutured and rats returned to their home cage.
Confirmation of Viral Transduction
Rats were deeply anesthetized and transcardially perfused with
10% formalin. The brains were removed, incubated in 10%
formalin overnight (4◦C) while shaking, followed by at least
24 h in a 25% sucrose/phosphate buffered saline (PBS) solution.
Free-floating sections (40 µm) were obtained and stored in
0.2% sodium azide-PBS at 4◦C. To confirm placement and
viral spread, floating sections were either mounted in Prolong
Gold media (Invitrogen) to analyze native EGFP fluorescence,
or processed for GFP immunohistochemistry. Tissue sections
were incubated with a 1% H2O2 phosphate buffered saline-
tween20 (PBST) solution for 30 min, rinsed three times with
PBS, and incubated with a rabbit anti-GFP antibody (Invitrogen,
catalog no. A6455) 15–18 h at room temperature. Sections were
rinsed three times with PBS and incubated with biotin-SP-
conjugated AffiniPure Donkey anti-Rabbit IgG (H + L) (Jackson
ImmunoResearch Labs, cat. no. 711-065-152) for 1 h. After
rinsing another three times with PBS, the sections were incubated
with ABC reagent (Vectorlabs cat. no. PK-6100), rinsed another
three times with PBS and stained with diaminobenzidine (DAB,
Sigma). Sections were then mounted and coverslipped with
Permount. Only rats that exhibited correct placement with viral
spread restricted primarily to the SN were included in the
analyses, while rats demonstrating spread overlapping with the
VTA were excluded.
Real-Time Quantitative PCR
A cohort of rats was unilaterally infused with 1.0 µl of D2R
(n = 6) or SCR shRNA virus (n = 4) in the SN and sacrificed
by decapitation 2–4 weeks later under deep anesthesia induced
with ketamine and xylazine. Two mm coronal brain punches
were taken at both the injection site and the contralateral
uninjected side. Total RNA was isolated from each punch
with an RNeasy Micro Kit (Qiagen, Hilden, Germany),
eluted with 14 µl of ribonuclease-free water and stored at
−80◦C. RNA quantification and purity was determined with
purity set at a 260/280 ≥ 2.0 and 260/230 ≥ 1.8 (NanoDrop
1000 Spectrophotometer, Thermo Scientific, DE, USA). Total
RNA (500 ng) was reverse transcribed into cDNA using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
CA, USA) according to the manufacturer’s instructions.
Real-time qPCR was performed in triplicate for each sample
using a Bio-Rad Miniopticon Real-Time PCR system (Bio-rad,
Hercules, CA, USA). Sybr assays were used to determine the
expression of the following genes: rat Enolase 2 (ENO2), rat
D2 dopamine receptor (DRD2), rat beta-actin (BACT) and
EGFP. The following primer sets were used in these experiments.
ENO2: ACGTCTGGCGAAGTACAACC (forward), GTCGGGA
CAGCAAGAAAGAG (reverse), BACT: CATCCTGCGTC
TGGACCTGG (forward), TAATGTCACGCACGATTTCC
(reverse). The DRD2 and tyrosine hydroxylase (TH) genes
was quantified using the Bio-Rad PrimePCRTM Sybrr Assay
(qRnoCID0001883 and qRnoCID0002299, respectively). The
stably expressing housekeeping gene BACT was used as a
reference genes and relative quantification of gene expression
levels was assessed using the comparative CT method (2−∆∆CT
method; Livak and Schmittgen, 2001). SN punches that did not
contain GFP were considered a missed infusion and not included
in the analyses. The difference between the means was evaluated
by a Student’s t-test and differences at the P < 0.05 level were
considered significant.
Fast Scan Cyclic Voltammetry (FSCV)
A cohort of rats was injected with either the shD2R-EGFP-
AAV10 or shSCR control virus in the SN and 2 weeks later
the ability of haloperidol to alter DA release and reuptake was
determined using voltammetry. While under urethane anesthesia
(1.5 g/kg, i.p.), rats were secured in a stereotaxic frame in a flat
Frontiers in Behavioral Neuroscience | www.frontiersin.org 3 January 2017 | Volume 10 | Article 248
Budygin et al. SN D2 Effects on Dopamine
skull position. Holes were drilled into the skull above the striatum
for the detecting electrode (AP: +1.3, ML: +1.5 (±0.2) in mm
relative to bregma) and SN for the stimulating electrode (AP:
−5.6, ML: +2.0 mm). An additional hole was drilled into the skull
of the contralateral hemisphere into which an Ag/AgCl reference
electrode was implanted just below the surface of the skull. A
carbon fiber microelectrode (approximately 80–200µm in length
beyond the glass capillary in which it was contained) was secured
to the stereotaxic frame arm and also connected to the amplifier.
The carbon fiber electrode was placed into the hole above the
striatum, and lowered approximately 5 mm from the surface
into the striatum. Voltammetric recordings were made at the
recording electrode every 100 ms for a 15 s duration by applying
a triangular waveform (−0.4 to +1.2 V, 400 V/s). The biphasic
stimulation applied by the stimulating electrode consisted of
60 rectangular pulses at 60 Hz, 300 µA and was activated at
5 s into each recording. Recorded signals showed an oxidation
peak at +0.6 V and a reduction peak at −0.2 V (vs. Ag/AgCl
reference), ensuring that the released chemical was indeed
DA. The carbon fiber microelectrode and bipolar stimulating
electrode were independently positioned at depths of 4.6–5.2 mm
and 7.5–8.3 mm, respectively, to optimize the amplitude of
electrically evoked DA release. Once evoked DA recordings were
optimized, stable readings were collected every 5 min for at
least 20 min. When baseline recordings were within 10% of
each other for at least five measurements, haloperidol or saline
was injected. Stimulated recordings were then made at 1, 5 and
10 min and thereafter every 10 min up to 120 min following drug
injection. Data were digitized (National Instruments, Austin, TX,
USA) and stored on a computer. Carbon fiber microelectrodes
were post-calibrated in vitro with known concentrations of DA
(2–5 µM). Calibrations were performed in triplicate and the
average value for the current at the peak oxidation potential
was used to normalize recorded in vivo current signals to DA
concentration. DA uptake was determined from the clearance
rate of DA and was assumed to follow Michaelis-Menten kinetics.
The changes in DA during and after electrical stimulation were fit
using the equation:
d [DA] /dt = ((f )[DA]p − (Vmax/{(Km/ [DA]) + 1}))
where f is the stimulation frequency (Hz), DA release per pulse
[DA]p is the concentration of DA released per stimulus pulse,
andVmax is the maximal rate of DA uptake, which is proportional
to the number of DAT proteins. The baseline value of Km was
calculated to be between 0.16–0.2 µM, a value determined in
rat brain synaptosomes and commonly used in the analysis of
voltammetric data (Near et al., 1988; Garris and Rebec, 2002).
The derivative form of the above equation was used to simulate
the DA response (Garris et al., 1997; Budygin et al., 1999a; Wu
et al., 2001; Garris and Rebec, 2002; Oleson et al., 2009a,b).
Rats were injected with saline, 0.5 or 1.0 mg/kg haloperidol i.p.
(n = 5 per dose) and the effects on DA release and reuptake
measured.
Behavioral Tests
Rats serving to assess the effect of SN D2 knockdown on
behavior were injected with 0.5 µl virus as described above. The
experimenter was blind to which virus the rats received. The
first cohort of rats was acclimated to the open field chambers
(17 × 17 × 12 inch, Med-Associates) for 1 h and total distance
traveled (in cm) was recorded during 12, 5-min consecutive
bins for three consecutive days prior to surgery. One week after
surgery locomotor activity was again measured and subsequently
tested once a week for a total of 8 weeks post-surgery. Another
cohort was challenged 4 weeks after viral infusions in a Latin
square design with saline, 0.5, 1.0 or 2.0 mg/kg haloperidol i.p.,
to evaluate the effects of haloperidol induced catalepsy using the
bar test. Each rat received only one dose per day with 3 days
between doses. One hour after injection the front paws of the
rats were placed on a metal bar (1 cm in diameter, positioned
9 cm above the surface) and the amount of time until both paws
were removed and returned to the table surface was measured,
with a 3 min maximum time allowed. After an additional week
for washout the rats were placed in the open field chambers and
following 30 min of acclimation challenged with saline, 5, 10 or
20 mg/kg cocaine i.p. in an escalating dose design to evaluate the
entire dose-response curve, with challenges occurring at 4 day
intervals. Data are presented as total distance traveled (m), and
% of saline response, where % saline response = m traveled
cocaine/saline × 100. An ascending dose response was chosen
for cocaine in an effort to minimize the effects of locomotor
sensitization.
Statistical Analyses
The data are presented as mean ± SEM and the criterion of
significance was set at p < 0.05. Real-time qPCR, voltammetry
and behavioral data were analyzed using t-test, one-way repeated
measures or two- way ANOVAs with a Bonferroni and
Simple Effects post-tests, respectively, to determine statistical
significance.
RESULTS
Site Specific Depletion of D2R from SN
Neurons and their Projections
In previous studies we established that the D2R shRNA viruses
significantly decrease both the mRNA and protein levels of the
post-synaptic D2R when injected directly into the dStr (Blume
et al., 2013). Here we demonstrate that D2R mRNA levels are
likewise significantly decreased after D2R shRNA-AAV infusions
into the SN. Immunohistochemistry for EGFP, which is also
produced by the D2R and SCR viruses, reveals the extent of
transduction. In Figure 1A we show the EGFP expression in the
SN from a representative rat 8 weeks after it was injected with
the D2R shRNA virus. EGFP expression was largely restricted
to the SN, and while both SN pars compacta (SNc) and
SN pars reticulata (SNr) were transduced, the SNc had more
prominent/dense signal. Missed infusions including spillover
into the VTA were excluded from all analyses. We have observed
detectable levels of EGFP in the SN within 3 days of infusing the
virus, with maximal expression achieved within 1–2 weeks post-
infusion, and expression lasting for at least 4 months (data not
shown). Expression of EGFP in the terminals is also observed
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in this time frame. Real time qPCR analysis revealed an ∼90%
reduction of D2R RNA expression when comparing rats infused
with D2 shRNA virus (Figure 1B) and those infused with the SCR
control virus (Figure 1C). Since AAV10 will transduce primarily
the neuronal cell bodies at the site of the injection (Cearley and
Wolfe, 2006), injection of the virus directly into the SN will
produce a knockdown in any neuronal cell body that expresses
D2 mRNA in this region, including dopaminergic neurons. The
D2 autoreceptor on dopaminergic terminals projecting from the
SN to the dStr as well as the somatodendritic D2 autoreceptors
should be affected. As long as the virus does not spread to
the VTA, the D2 autoreceptor population on the cell body and
projections for this population of DA neurons will be spared. In
addition, we observed no changes in D2 mRNA levels in dStr
neurons (Figure 1D).
Knockdown of SN D2R Alters DA
Dynamics in the Dorsal Striatum and
Attenuates the Ability of Haloperidol to
Enhance DA Release
Haloperidol enhances electrically-evoked DA release in the
striatum, primarily by blocking presynaptic D2 autoreceptors,
which disinhibits DA release and attenuates reuptake through
the DAT (Garris and Rebec, 2002; Garris et al., 2003). Therefore,
we hypothesized that knockdown of the SN D2 autoreceptor
would blunt haloperidol-induced increases in an electrically-
evoked DA release in the dStr. Two weeks after infusion of
the D2 shRNA-AAV into the SN, we assessed the effects of
haloperidol on DA release in the dStr using fast-scan cyclic
voltammetry. We chose an early time point in an effort to avoid
consequences of neurochemical compensation due to the loss
of the D2R over time. As predicted, 0.5 mg/kg of haloperidol
induced a significant increase in electrically-evoked DA release
in SCR treated control rats, and this effect was attenuated in the
SN D2 knockdown animals (F(1,60) = 27.42, p< 0.0001; two-way
ANOVA). Figure 2A shows color plots from representative
SCR control and SN D2 knockdown rats, prior to treatment
with 0.5 mg/kg haloperidol i.p. The time course of 0.5 mg/kg
haloperidol on electrically evoked DA release is presented in
Figure 2B. When normalized to baseline levels (% predrug),
0.5 mg/kg haloperidol significantly increased maximal evoked
DA release in SCR controls (Bonferroni’s p < 0.05), an effect
that was absent in SN D2 knockdown rats (Figure 2C). When
a higher dose of 1.0 mg/kg haloperidol was tested both groups
of rats exhibited a significant increase in electrically evoked DA
release compared to their predrug baseline; however, the increase
was greatly attenuated in SN D2 knockdown rats compared to
SCR controls, and these two groups were significantly different
from one another (Bonferroni’s p< 0.05).
To evaluate DA release and uptake changes following
SN D2 knockdown we used kinetic analysis of the baseline
electrically evoked fast-scan cyclic voltammetry data, based
on the neurochemical model developed by Wightman
(Near et al., 1988). As described previously, the analysis
evaluates measured electrically-induced DA efflux in terms
of one parameter for DA release and two parameters of
FIGURE 2 | SN D2 autoreceptor knockdown blocks haloperidol
induced enhancement of electrically evoked dopamine (DA) release.
(A) Left panels display fast scan cyclic voltammetry (FSCV) data from a
representative SCR virus control animal while panels on the right are from a
representative SN D2 autoreceptor knockdown rat. Measurements were taken
in the dStr over a 15 s period. Top panels demonstrate concentrations vs.
time traces extracted from the data at 0.65 V; the peak oxidation for DA.
Bottom panels represent standard color plots, which topographically depict
the voltammetric data before haloperidol injection with time on the x-axis,
applied scan potential on the y-axis and background-subtracted faradaic
current shown in the z-axis in pseudo-color. The identical color plots were
obtained following haloperidol administration with the exception that
background-subtracted current at 0.65 V was noticeably stronger.
(B) Represents a time course of electrically evoked DA release normalized to
pretreatment amounts (first three measurements). The mean electrically
evoked DA release (% of evoked DA release in pre-haloperidol
measurements) ± SEM are graphed (n = 8–10), measurements were taken
every 5 min for 1.5 h. The blue arrow indicates administration of 0.5 mg/kg
haloperidol immediately after the third baseline measurement was taken.
(C) Demonstrates the mean maximal electrically evoked DA release ± SEM
achieved in the 90 min after 0.5 or 1.0 mg/kg haloperidol i.p. Data were
analyzed with one-way ANOVA followed by Bonferonni post hoc tests.
Dashed line indicates 100% of pre-drug levels, ∗ indicates a significant
difference from the rats pre-drug baseline measurements (∗p < 0.05), while #
indicates a significant difference from baseline as well as the corresponding
SN D2 autoreceptor knockdown rats treated with the same dose of
haloperidol (#p < 0.05).
DA uptake. These parameters were determined by fitting
experimental results to curves simulated by the model (Bass
et al., 2010). The analysis of the electrically evoked DA
signals indicated that [DA]p was significantly decreased
following SN D2 knockdown (p < 0.005, t = 3.321, df = 16;
Unpaired t test; Figure 3A). Similar changes were found with
the parameter of DA uptake, Vmax, which decreased from
3715 ± 255 nmol/s in SCR control rats to 1711 ± 428 nmol/s
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FIGURE 3 | Altered DA release and reuptake kinetics in SN D2 autoreceptor knockdown rats. Electrically evoked DA release during baseline
measurements were analyzed and the mean ± SEM kinetic parameters of (A) DA per pulse, (B) Vmax, (C) Km and (D) maximal amplitutes (µM) are graphed
(n = 8–10, ∗p < 0.05).
in SN D2 knockdown rats (p < 0.005, t = 4.024, df = 14;
Unpaired t test; Figure 3B). At the same time, no significant
alterations in the second Michaelis-Menten parameter for DA
uptake, apparent Km, were seen (190 ± 7 vs. 201 ± 9 nM
for SCR control and D2 knockdown group, respectively,
Figure 3C). Maximal amplitude of electrically-evoked
DA efflux was also not affected by SN D2 knockdown
(1.06 ± 0.09 vs. 0.85 ± 0.14 µM, Figure 3D) which is in
agreement with proportional changes in [DA]p and Vmax.
Together these data indicate that loss of the D2 autoreceptor
from SN terminals in the dStr attenuates the ability of
haloperidol to enhance DA release, and that a consequence
of D2 autoreceptor depletion is a decrease in Vmax or reuptake
by approximately 56%.
Depletion of D2R from the SN Is
Associated with Locomotor Hyperactivity
and Loss of Habituation
We next examined the effect of SN D2 knockdown on locomotor
activity over time. Rats were allowed 1 week to recover before
testing in an open field activity chamber and were assessed
each week thereafter for 2 months (Figure 4). Analysis of the
total distance traveled in the eight weekly sessions revealed
a significant interaction between virus and week (two-way
repeated measures ANOVA, F(7,98) = 3.53, P = 0.002). Post hoc
analysis using Simple Effect tests (Winer, 1962) showed a
significant increase in total distance traveled in the SN D2R
knockdown rats starting at week 2 and no change in total
distance traveled each week in SCR controls over the 8 week
period. Total distance traveled by SN D2R knockdown rats
became significantly greater than that of SCR controls at 5 weeks
and continuing through 8 weeks, the last time point measured
(for Simple Effect test of Virus at each week, see Table 1).
A post hoc exploratory analysis was conducted on bin data
during weeks 5–8 to further explore the pattern of change in
locomotor activity over the 60 min session and to test the idea
that SN D2R knockdown might modify the pattern of within
session habituation. A two-way ANOVA comparing locomotor
activity by 5-min bins (averaged over weeks 5–8) between SCR
and SN D2R knockdown rats found a significant interaction
between virus and bin (Simple Effects Test, F(11,154) = 2.36,
p = 0.01) in which differences in locomotor activity between
SN D2 knockdown rats and SCR controls occurred in bin
5 and bins 7–12 only (Simple Effects tests, p < 0.05, see
Table 2). The magnitude of the difference increased with
time to peak at bin 9 and then leveled off. Among SCR
controls, and as expected, there was a significant decrease in
locomotor activity across bins (Simple Effects test comparing
bins in SCR, F(11,154) = 5.56, p < 0.0001); locomotor activity
decreased significantly in bin 1, 2 and 3 and then leveled off.
Among SN D2 knockdown rats, no significant difference in
locomotor activity by bin was observed (Simple Effects test,
F(11,154) = 1.81, p = 0.0695). The pattern of these results
suggests that the change in locomotor activity consequent to
SN D2 knockdown lies in part in the reduction or absence
of within session habituation. The hyperactivity exhibited by
the SN D2R knockdown rats is similar to that reported for
global D2 autoreceptor knockdown mice by Bello et al. (2011).
However, in the Bello et al. (2011), study both wildtype and
D2 autoreceptor knockouts demonstrated a progressive decrease
in distance traveled with each successive bin within a session
as the mice habituated to the chamber. In our model, we
saw a similar pattern in both the SCR and D2R shRNA
rats during the first 4 weeks, but with subsequent weeks the
shape of this curve began to change in SN D2 knockdown
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FIGURE 4 | Effect of SN D2 autoreceptor knockdown on spontaneous locomotor activity. Each panel represents a 1-h session in which distance traveled
was measured in 5-min bins. Circles represent the mean ± SEM of either D2 shRNA-AAV (red) or SCR shRNA control AAV (white) injected rats. The rats were tested
weekly after virus infusion on the same day of the week and at the same time of day. Data were analyzed by comparing total distance traveled (last panel) by each
virus group over each post-injection week using a repeated measures two-way ANOVA. The last panel on the lower right shows the total distance traveled for the
entire 1-h weekly sessions. ∗ Indicates a significant difference with p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001.
rats, in which the typical decrease in locomotor activity with
successive bins during the session either reversed or was absent
(Figure 4).
Decreased Haloperidol-Induced Catalepsy
in SN D2 Knockdown Rats
The ability of haloperidol to induce catalepsy was tested in a
separate cohort of SN D2 knockdown rats 7 weeks after virus
infusion into the SN. As indicated in Figure 5A, SCR control
virus injected rats exhibited dose dependent increase in the
time needed to remove both paws from the bar and return
them to the table surface. However, the ability of haloperidol
to elicit this response was reduced in SN D2 knockdown rats.
Two-way ANOVA with repeated measures on dose found a
significant interaction between dose and virus (F(3,54) = 7.724,
p = 0.0002) and a significant main effect of each variable (dose
F(3,54) = 43.78, p < 0.0001, virus F(1,18) = 14.15, P = 0.0014).
Post hoc tests (Simple Effect tests) of the effect of dose in
SCR control rats (F(3,54) = 39.8, p < 0.0001) showed that
haloperidol significantly increased the time on the bar at
each dose (in mg/kg, 0.0 < 0.5 < 1.0 < 2.0 by Student
Neumann-Keuls pairwise comparison test). In contrast, the
effect of dose in SN D2 knockdown rats (F(3,54) = 8.50,
p < 0.001) showed that haloperidol significantly increased
time on the bar at 1.0 and 2.0 mg/kg doses only (in mg/kg,
0 = 0.05 and 0 < 1.0 < 2.0). Furthermore, time on the bar
was significantly reduced in SN D2 knockdown rats relative to
SCR control rats at the two highest doses of 1.0 (F(1,63) = 18.9,
p < 0.0001) and 2.0 (F(1,63) = 27.0, p < 0.0001) mg/kg doses
only.
Even though the behavioral assay demonstrated less catalepsy
at each dose there were some qualitative haloperidol-induced
behavioral deficits that the experimenter could distinguish from
vehicle injected subjects. Abnormal rigid postures, associated
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TABLE 1 | Summary of spontaneous locomotor activity.
Mean total distance traveled (cm) In 1 h ± SEM
Time (weeks) SCR control shRNA D2R shRNA F(1,23)
Baseline 6152 ± 415 6269 ± 422
1 5049 ± 402 6602 ± 505 <1
2 5367 ± 573 10621 ± 1520 1.72
3 5976 ± 736 12724 ± 2478 2.89
4 6169 ± 793 13177 ± 3088 3.11
5 5578 ± 639 14149 ± 4352 4.65∗
6 4842 ± 660 16394 ± 5005 8.46∗∗
7 5254 ± 650 17012 ± 4955 8.47∗∗
8 5422 ± 865 18435 ± 5981 10.73∗∗
∗Significant difference with p < 0.05 and ∗∗ p < 0.01.
with akinesia, were often observed in the home cage in both the
SN D2 knockdowns and SCR controls after receiving haloperidol.
However, the D2 knockdowns that displayed rigidity in their
home cage were mobile when placed on the bar and quickly
returned to four paws, however they did so with uncoordinated,
erratic movements.
Knockdown of Dorsal Striatal
D2 Receptors Alters Responsiveness to
Cocaine Induced Locomotor Effects
The ability of cocaine to enhance locomotor activity was assessed
in SN D2 knockdown rats and SCR controls using an escalating
dose paradigm, with 4 days between challenge cocaine doses.
As expected, SCR virus treated rats exhibited a dose responsive
increase in locomotor activity when challenged with cocaine
(Figure 5B). Repeated measures two-way ANOVA found a
significant main effect of dose (F(3,24) = 9.667, p = 0.0002),
no main effect of virus (F(1,8) = 2.509, p = 0.1519), and
no significant interaction between dose of cocaine and virus,
(F(3,24) = 1.327, p = 0.2890). However, it was noted that there was
substantial variability in the baseline locomotor response among
the rats (i.e., locomotor response to a saline injection), and no
significant group differences (F(1,8) = 1.264, p = 0.293) to which
this variability could be ascribed. Therefore, we transformed
the data to a percent of saline response to constrain the
variability (Figure 5C). When normalized in this fashion, a
significant interaction between virus and dose of cocaine is found
(F(2,16) = 4.33, p = 0.031). Simple Effect tests were used to probe
the interaction and showed that the locomotor response of SN
D2 knockdown rats to 5 mg/kg cocaine is not significantly greater
than SCR control rats (F(2,17) < 1.0), but that the response to
20 mg/kg dose is significantly less in SN D2 knockdown rats than
SCR control rats (F(2,17) = 6.08, p< 0.01). This pattern of change
was also noted in the analysis of dose by virus which revealed
that although there was an effect by dose in the SCR control rats
(F(2,16) = 19.23, p< 0.0001), there was no effect of dose in the SN
D2 knockdown rats (F(2,16) = 2.08, p = 0.1574).
DISCUSSION
The role of the presynaptic D2 autoreceptor in the regulation
of striatal DA neurotransmission in distinct circuitries
(nigrostriatal vs. mesolimbic) is not completely understood,
due in large part to the lack of dopaminergic reagents that can
independently modulate the pre- and postsynaptic D2R pools.
Thus, a genetic approach is necessary to achieve specificity in
targeted manipulations of the autoreceptor. We have previously
shown that RNAi is an effective approach to manipulate D2R
subpopulations, by specifically knocking down D2R expression
in the dStr (Blume et al., 2013). Here we demonstrate for the first
time depletion of the D2 from SN neurons exclusively without
also manipulating the post-synaptic D2R, or D2R in the VTA
and on mesolimbic dopaminergic projections.
Two D2 autoreceptor knockout mouse strains have
been created recently; however, these strains have the
D2 autoreceptor deleted globally throughout the entire
brain and from conception, which limits understanding of
regional contributions and is confounded by the potential for
developmental neuroadaptations. In addition, there are distinct
differences in the phenotypes of the two D2 autorecpetor
knockout (D2autoKO) transgenic mice generated thus
far. For example, the mice produced by Bello et al. (2011)
exhibited no change in DA uptake, an increase in electrically
evoked DA release and hyperactivity in novel and familiar
environments (Bello et al., 2011), while the Anzalone et al
mutant produced opposite results including increased DA
uptake, decreased electrically evoked release and hyperactivity
only in novel environments but not the farmiliar home cage
environment (Anzalone et al., 2012). As the authors in the
Anzalone study pointed out, one possible explanation for these
discrepancies is that the Dat+/IRES–cre line used to generate the
Bello DAT-D2autoKO mice likely produce less Cre in cortical
regions, as these areas naturally have less DAT expression
(Freed et al., 1995; Sesack et al., 1998). Therefore, the resulting
mutants may potentially retain some D2 autoreceptor in these
cortical regions. In addition, the Dat+/IRES–cre line also has
reduced expression of the DAT overall compared to wildtype
mice, potentially further confounding DA neurotransmission
experiments with this resulting Bello mutant (Bäckman et al.,
2006). However, it is important to note that the En1Cre
used in the Anzalone study is not well characterized in the
literature, and may have incomplete or ectopic expression
issues as well. In addition, the global nature of the knockout in
both studies, from numerous cortical and subcortical regions,
undoubtedly confound the underlying regional contributions of
the D2 autoreceptor to a particular behavior. The current study
uses RNA interference to manipulate D2R expression specifically
in SN neurons of adult rats. The specific advantage of RNAi is
the ability to manipulate pre- and postsynaptic receptor pools
from discrete brain regions in adult, wildtype animals, thereby
avoiding developmental compensation and allowing mapping of
the effect to a discrete receptor pool. In addition, depletion of the
receptor, vs. the total deletion in a knockout, allows us to study
graded responses.
In an attempt to understand how depletion of the
D2 autoreceptor affects DA neurotransmission in the dStr, we
injected the D2 shRNA virus in the SN and examined electrically
evoked DA release and reuptake kinetics in the dStr. Analysis
of DA kinetics revealed pronounced alterations in electrically
evoked DA signals, including a decrease in [DA] per pulse and
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TABLE 2 | Summary of Locomotor activity (average week 5–8).
Bin SCR SN D2 KD F(1,19) p
1 1333t 1675 <1 NS
2 752t 1334 1.58 0.22
3 471t 1206 2.53 0.128
4 360 1106 2.61 0.1227
5 283 1269 4.56 0.046∗
6 287 1201 3.93 0.0621
7 271 1237 4.39 0.0498∗
8 266 1505 7.21 0.0147∗
9 259 1539 7.69 0.0121∗
10 344 1497 6.36 0.0208∗
11 343 1396 5.2 0.0343∗
12 314 1530 6.94 0.0163∗
tSignificantly different than all other bins in that group (p < 0.05). ∗Significant
difference between SCR and SN D2 KD (p < 0.05).
Vmax (Figures 3A,B), while Km was not affected (Figure 3C).
Our observations are in sharp contrast to the transgenic
D2 autoreceptor knockout mutants, in which DAT uptake was
not altered (DAT-D2autoKO mouse) or enhanced DA reuptake
was observed (Eng1-D2autoKO mouse). An obvious explanation
for these discrepancies between models are species differences in
the neuroanatomy, DA kinetics or D2 expression levels between
mice and rats. It is also plausible that these discrepancies in
DAT function between our acute genetic manipulation in adult
rats and the conditional D2 knockout mouse strains may reflect
a developmental neuroadaptive increase in DAT activity to
compensate for the hyperdopaminergia observed in these latter
animals. There is strong evidence that the D2 autoreceptor
and DAT interact physically and that this interaction facilitates
trafficking of the DAT to the cell surface (Bolan et al., 2007;
Eriksen et al., 2010; Chen et al., 2013). Disruption of physical
D2-DAT interactions inhibits normal cell surface expression
of the DAT (Lee et al., 2007). Furthermore, the DAT is known
to be regulated in a variety of ways, including through βγ
dimers (Garcia-Olivares et al., 2013) and a variety of interacting
proteins (for review see Sager and Torres, 2011). Finally, we
also examined the effect of D2R antagonism on DA kinetics in
the dStr. Haloperidol administration under normal conditions
(Garris et al., 2003), and in the SCR control animals (Figure 2),
enhances electrically evoked DA release, an effect that has
previously been attributed to antagonism of the D2 autoreceptor.
Not surprisingly, the depletion of the D2R from the SN greatly
attenuated the ability of haloperidol to enhance DA release in
the dStr, and is an important pharmacological confirmation that
the D2R was depleted from presynaptic terminals.
In terms of the behavioral consequences of the SN
D2 knockdown, our rats displayed a phenotype characterized by
hyperactivity, lack of habituation during open field exposure, and
altered sensitivities to dopaminergic drugs. In many ways our
model recapitulated the phenotype observed in the transgenic
D2autoKO mice. For example, the SN D2 knockdown rats
developed significant increases in locomotor activity within
2 weeks of virus infusion (Figure 4). This hyperactivity was
long-lasting and progressive. Moreover, the hyperactivity was
expressed in a familiar environment as the rats were repeatedly
exposed to the open field chambers. However, unlike the
DAT-D2autoKO mice, the SN D2 knockdown rats failed to
show the typical within session habituation to the open field
chamber. Interestingly, a similar lack of habituation has been
observed in a DAT knockdown mouse, in which DAT levels are
depleted to 10% of wildtype levels (Zhuang et al., 2001). The
DAT knockdown mutants are hyperactive and have impaired
response habituation, particularly in novel environments, a
phenotype the authors attributed to an imbalance between pre-
and post-synaptic D2 function. We observed a similar decrease
in dopaminergic function in the SN D2 knockdown rats, where
depletion of the SN D2R is associated with a decrease in Vmax
FIGURE 5 | Altered sensitivity to dopaminergic drugs in SN D2 knockdowns. (A) Catalepsy induced by the D2 antagonist haloperidol was measured as time
immobile in the bar test. Circles represent the mean amount of time immobile ± SEM. †Significantly different from saline p < 0.05, # significantly different from all
other doses p < 0.01, ∗∗∗ significantly different between virus groups at p < 0.0001. Black and red marks correspond to the scr and D2R shRNA data points,
respectively. In a separate cohort of animals, the ability of the DA transporter (DAT) blocker cocaine to enhance locomotor activity was tested and measured as
distance traveled (B) and transformed as percent of saline (C). With both drugs a dose response was conducted in either a randomized order (haloperidol) or in an
ascending fashion (cocaine) with 3 days between doses to allow for elimination of the drug. Circles represent the mean distance traveled ± SEM (B), or % of saline
distance traveled (C) of either D2 shRNA-AAV (red) or SCR shRNA control AAV (white) injected rats (n = 5–11). ∗ Indicates a significant difference with p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001.
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(Figure 3B), indicating that DAT function is reduced through a
decrease in the amount of functional DAT (for review see Eriksen
et al., 2010). The was no apparent change in either habituation
or DAT function in DAT-D2autoKO mice. Together, the results
from the DAT knockdown mutant mice and our D2 knockdown
rats support the hypothesis that D2 autoreceptors in the dStr
mediate habituation by alterations in DAT function.
The SN D2 knockdowns rats also displayed a decreased
sensitivity to catalepsy induced by the atypical antipsychotic
haloperidol (Figure 5A). In contrast, the Anazolone study
demonstrated enhanced catalepsy in D2autoKO at a low dose
of haloperidol, and the Bello et al D2autoKO mouse exhibited
supersensitivity to haloperidol-induced inhibition of locomotor
activity at relatively low doses. Blockade of the presynaptic
D2 autoreceptor by haloperidol increases electrically evoked
DA release (Figure 3), via the inhibition of autofeedback
mechanisms (Garris et al., 2003). Indeed, our results clearly
demonstrate that depletion of the SN D2R significantly decreases
haloperidol-induced enhancement of electrically-evoked DA
release (Figure 3). However, it is believed that the motoric side
effects of haloperidol, such as catalepsy, are preferentially due
to post-synaptic mechanisms (Klemm, 1985; Wadenberg et al.,
2000). There are several possible explanations for decreased
cataleptic activity in the SN D2 knockdown rats. Since activation
of the D2 autoreceptor decreases DA synthesis and release
(Budygin et al., 1999a; Joseph et al., 2002) and increases
DA reuptake, the knockdown of the D2 could produce the
opposite effects, resulting in an augmentation of dopaminergic
tone. Under these conditions, more haloperidol may be needed
to block this enhanced DA tone at post-synaptic D2R sites.
Our behavioral results support this notion, as rats showed an
increase in locomotor activity implying that the animals may
be hyperdopaminergic. In addition, the FSCV results support a
decrease in DA reuptake. However, the decrease in electrically-
evoked DA release that does not suggest an augmentation in
DA synthesis, while it cannot exclude an increase in basal DA
efflux. Indeed, it is highly possible that the D2R removal from
somatodendritic locations leads to an increased firing rate of
DA neurons in the SN. We also cannot exclude a scenario
in which the D2 knockdown is accompanied by compensatory
alterations (increased sensitivity or density) in other presynaptic
receptors, most notably the D3 receptor which has also been
extensively implicated in the presynaptic regulation of DA
release in the striatum (Gainetdinov et al., 1994, 1996; Joseph
et al., 2002). This receptor has a much higher affinity for DA
than the D2 DA receptor (Sokoloff et al., 1990), therefore, the
decrease in electrically-evoked DA could be a consequence of the
D3 receptor activation. Although the presynaptic D3 receptor
appears to have a smaller role than D2 in regulating DA
release under normal circumstances, it is possible that D3 could
be upregulated or develop a more prominent role in the SN
D2 knockdown rats.
The SN D2 knockdown rats also demonstrated altered
responses to the locomotor stimulatory effects of cocaine. When
normalized to baseline levels, the magnitude of the increase
in locomotor activity among SN D2 knockdown rats after
a high dose (20 mg/kg) of cocaine was in fact significantly
less compared to SCR controls. These data are opposite to
those observed in the D2autoKO transgenic mice, which
exhibited an enhanced locomotor response to low and moderate
doses of cocaine. The most probable explanation of these
discrepancies is that deletion of D2 specifically from mesolimbic
projections, but not nigrostriatal, contribute to the enhanced
sensitivity to the locomotor effects of cocaine exhibited by the
D2autoKO mice. There is evidence of functional selectivity in
dopaminergic projections, with mesolimbic appearing to mediate
locomotor effects of psychostimulants while nigrostriatal are
more important for associated stereotypies (Amalric and Koob,
1993). In addition, it may be that the magnitude of effects
of cocaine observed in these mouse models would not be as
pronounced if the data were analyzed as a percentage of drug
naïve or saline responses. Finally, since we used an escalating
dose response, it is possible that a decrease in the development of
cocaine sensitization in SN D2 knockdown rats may lead to this
outcome. Regardless, our data highlight the importance of the
D2 autoreceptor in setting the dynamic range and sensitivity to
dopaminergic agents, even those that do not act directly through
the D2R.
Perhaps the most surprising aspect of the acute depletion
of SN D2R is the possible existence of neuroadaptations to
the acute D2 knockdown. As discussed above, there may be
compensatory expression or increased sensitivity of presynaptic
D3 receptors as well as other possible adaptations, which could
develop during a short period, including changes in the firing
rate of DA cell bodies. However, this last one will be difficult to
separate from the direct consequences of the D2 presynaptic DA
receptor removal. Presumably similar mechanisms are at work in
the transgenic mice as well, although undoubtedly alterations of
these pathways in the developing animals can lead to additional
compensatory alterations. Thus, our approach may be better
suited for examining the development of both early and later
adaptations, and could perhaps mimic adaptations of long term
D2 antagonist drug treatments that are therapeutically applied
in adolescence or adulthood. These results reinforce the need to
understand the mechanisms underlying neuroadaptations that
arise from manipulating DA neurotransmission.
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